Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Epidermal growth factor receptor (EGF-R) overexpression in tumors correlates with poor clinical outcomes.
• Monoclonal antibodies targeting EGF-R are under development for cancer therapy.
• The study focuses on the efficacy of anti-EGF-R antibody EMD 55900 in breast cancer.

Purpose of the Study:

• To evaluate the therapeutic potential of anti-EGF-R antibody EMD 55900 for breast cancer treatment.
• To determine the relationship between EGF-R expression levels and therapeutic response.
• To assess treatment efficacy in different tumor development stages.

Main Methods:

• Analysis of EGF-R expression in 299 breast cancer specimens.
• Generation of primary breast cancer xenotransplants in athymic nude mice.
• Administration of EMD 55900 therapy in two distinct treatment schedules.
• Evaluation of therapeutic response based on EGF-R expression levels (10-300 fmol/mg).

Main Results:

• A therapeutic effect was observed in tumors with EGF-R expression levels of at least 40 fmol/mg.
• The study utilized 6 different tumors with varying EGF-R expression for testing.
• Treatment efficacy was assessed in both early-stage and established tumors.

Conclusions:

• Up to 15% of breast cancer patients may benefit from EMD 55900 monotherapy.
• EGF-R expression level is a critical factor in predicting response to EMD 55900 therapy.
• EMD 55900 represents a potential targeted therapy for a subset of breast cancer patients.